ARO-SOD1 / Arrowhead - LARVOL DELTA

Study of AROSOD-1 in Adult Participants With Amyotrophic Lateral Sclerosis (ALS) (clinicaltrials.gov) - P1 | N=0 | Withdrawn | Sponsor: Arrowhead Pharmaceuticals | N=32 ➔ 0 | Not yet recruiting ➔ Withdrawn

Enrollment change • Trial withdrawal • Amyotrophic Lateral Sclerosis • CNS Disorders • SOD1

Study of AROSOD-1 in Adult Participants With Amyotrophic Lateral Sclerosis (ALS) (clinicaltrials.gov) - P1 | N=32 | Not yet recruiting | Sponsor: Arrowhead Pharmaceuticals | Initiation date: Oct 2023 ➔ Jan 2024

Trial initiation date • Amyotrophic Lateral Sclerosis • CNS Disorders • SOD1

Arrowhead Pharmaceuticals to Participate in Upcoming October 2023 Conferences (Businesswire) - "Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: (i) 2023 Annual Northeast Amyotrophic Lateral Sclerosis Consortium (NEALS) Meeting – October 4-6, 2023: Date: October 5, 2023; Type: Poster Presentation; Title: Preclinical Profile of ARO-SOD1, an siRNA Therapy for SOD1-ALS....(ii) The 3rd International Research Conference on Neurodegenerative Diseases (IRCND 2023) – October 20-23, 2023: Date: October 22, 2023; Type: Oral Presentation; Title: Preclinical Profile of ARO-SOD1, an siRNA Therapy for SOD1-ALS."

Preclinical • Amyotrophic Lateral Sclerosis

Study of AROSOD-1 in Adult Participants With Amyotrophic Lateral Sclerosis (ALS) (clinicaltrials.gov) - P1 | N=32 | Not yet recruiting | Sponsor: Arrowhead Pharmaceuticals

New P1 trial • Amyotrophic Lateral Sclerosis • CNS Disorders • NEFL • Plasma NfL • SOD1

Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate a Phase 1 Study of ARO-SOD1 (Businesswire) - "Arrowhead Pharmaceuticals...today announced that it has filed an application for approval to initiate a Phase 1 clinical trial of ARO-SOD1, an RNAi-based investigational medicine designed to reduce expression of superoxide dismutase 1 (SOD1) in the central nervous system (CNS) as a potential treatment for patients with amyotrophic lateral sclerosis (ALS) caused by SOD1 mutations...Pending regulatory clearance, Arrowhead intends to proceed with AROSOD1-1001, a Phase 1 randomized, placebo-controlled, dose escalation study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of ARO-SOD1 in adult patients with ALS harboring a SOD1 mutation considered to be causative of ALS. The study is designed to enroll up to 24 subjects. An application was submitted to an ethics committee in compliance with the Clinical Trial Notification process of the Australian Department of Health and Ageing, Therapeutic Goods Administration."

New P1 trial • Amyotrophic Lateral Sclerosis • CNS Disorders